UPDATE IN THE MANAGEMENT OF DYSLIPIDEMIA 2013 RESDISUAL CV RISK AND SUBOPTIMAL LDL-C REDUCTION BEYOND STATINS J. Antonio G. López, MD FACC, FAHA, FACP, FACA, FCCP, FASE, FASA, FNLA, FASH Fellow, Council on Clinical Cardiology, American Heart Association Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association Fellow, Council on Epidemiology and Prevention, AHA Overseas Fellow, Royal Society of Medicine Specialist in Clinical Hypertension, American Society of Hypertension Diplomate, American Board of Clinical Lipidology Director, Preventive Cardiology and Cardiovascular Rehabilitation, Saint Alphonsus Regional Medical Center Director, Lipid Clinic and LDL Apheresis Program, Saint Alphonsus Regional Medical Center Chair, Department of Cardiology, Saint Alphonsus Regional Medical Center Chair Cardiovascular Research and Education, Saint Alphonsus Regional Medical Center President, Pacific Lipid Association SAINT ALPHONSUS MEDICAL GROUP HEART CARE
81
Embed
UPDATE IN THE MANAGEMENT OF DYSLIPIDEMIA 2013 RESDISUAL … · update in the management of dyslipidemia 2013 resdisual cv risk and suboptimal ldl-c reduction beyond statins j. antonio
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
UPDATE IN THE MANAGEMENT OF
DYSLIPIDEMIA 2013
RESDISUAL CV RISK AND SUBOPTIMAL
LDL-C REDUCTION BEYOND STATINS
J. Antonio G. López, MD FACC, FAHA, FACP, FACA, FCCP, FASE, FASA, FNLA, FASH
Fellow, Council on Clinical Cardiology, American Heart Association
Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association
Fellow, Council on Epidemiology and Prevention, AHA
Overseas Fellow, Royal Society of Medicine
Specialist in Clinical Hypertension, American Society of Hypertension
Diplomate, American Board of Clinical Lipidology
Director, Preventive Cardiology and Cardiovascular Rehabilitation, Saint Alphonsus Regional Medical Center
Director, Lipid Clinic and LDL Apheresis Program, Saint Alphonsus Regional Medical Center
Chair, Department of Cardiology, Saint Alphonsus Regional Medical Center
Chair Cardiovascular Research and Education, Saint Alphonsus Regional Medical Center
President, Pacific Lipid Association
SAINT ALPHONSUS MEDICAL GROUP HEART CARE
Presenter Disclosure
Information
DISCLOSURE INFORMATION:
The following relationships exist related to this presentation
(consultant and/or speakers bureau):
J. Antonio G. López, M.D., F.A.C.C., F.A.H.A. ,F.A.C.P.,
F.A.C.A., F.C.C.P., F.A.S.E., F.A.S.A., F.N.L.A.
Abbott Laboratories
Aegerion Pharmaceuticals
Amarin
AstraZeneca
Boerhringer Ingelheim
Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Daiichi Sankyo, Inc.
Diadexus
Forest Pharmaceuticals
Gilead
GlaxoSmithKline
Kowa Pharmaceuticals America, Inc.
Preventive Diagnostics
Takeda Pharmaceuticals
ZonaHealth
Objectives
• Discuss the importance of intensive LDL-C lowering strategy for addressing residual
Cardiovascular(CV) risk despite current optimal medical therapy
• Review the current pathophysiologic rationale for PSCK( inhibition in
hypercholesterolemia via a discussion of the mechanism of action and an analysis of
emerging clinical data.
• Describe the potential impact of emerging LDL-C targeted therapies in patients who
require additional LDL-C reduction, such as, those with familial hypercholesterolemia
and statin intolerance.
• Provide Recommendations
12
What Is Desirable Cholesterol?
50 70 90 110 130 150 170 190 210
Adult American
San
Pygmy
!Kung
Inuit
Hazda
Hunter-
gatherer
humans
Mean total cholesterol, mg/dL
Cholesterol Levels Among Different Human
Populations
Adapted from O’Keefe JH Jr et al. J Am Coll Cardiol. 2004;43:2142–2146.